Clinical Study of Compound Glycyrrhizin Tablets Combined with Recombinant Bovine Basic Fibroblast Growth Factor Gel for the Therapy of Facial Hormone-dependent Dermatitis / 中国药师

ABSTRACT

Objective:To explore the clinical effect of compound glycyrrhizin tablets combined with recombinant bovine basic fibroblast growth factor gel in the treatment of facial hormone-dependent dermatitis. Methods:Totally 108 patients with facial hormone-dependent dermatitis were selected randomly and divided into the control group(n = 54) and the treatment group(n =54). The control group was treated with desloratadine and 0.1% tacrolimus ointment;and the treatment group was treated with compound glycyrrhizin tablets combined with recombinant bovine basic fibroblast growth factor gel additionally on the basis of control group. The clinical efficacy of the two groups was evaluated,and the improvement of symptoms and objective signs before and after the treatment was compared. The adverse reactions were recorded as well. Results:The total effective rate of the treatment group after one-month and two-month treatment was 75.93% and 90.74%, respectively, which were both higher than those of the control group(P < 0.05). The scores of symptoms and objective signs and the total scores of disease of the treatment group after one-month and two-month treatment and two-month follow-up were all lower than those of the control group, and the differences were statistically significant(P <0.05). The disappearance time of objective signs and the incidence of facial adverse reactions were both lower than those of the control group,and the differences were statistically significant(P < 0.05),however, the incidence of dry mouth in the treatment group was higher than that in the control group(P < 0.05). Conclusion:Compound glycyrrhizin tablets combined with recombinant bovine basic fibroblast growth factor gel has better clinical effect for the therapy of facial hormone-dependent dermatitis,which can improve the symptoms significantly with high application security.